

28 August 2025

Our Ref: FOI 1323

Dear

**Freedom of Information Act 2000
Information in Relation to Oncology Myelofibrosis**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above, which you requested on 31 July 2025.

A response to the questions you have raised has been provided by the Surgery, Elective, Maternity and Paediatrics Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Olivia Robinson
Information Governance Officer

Q1a. How many patients were initiated on Ruxolitinib (Jakavi) in the past 6 months for the following conditions? (Patients are classed as initiated if they have not received any of the below treatments in the previous 6 months)?

- **Myelofibrosis (ICD-10 code: D47.4)**

A1a. In the past 6 months there has been 1 patient initiated on Ruxolitinib (Jakavi) for Myelofibrosis in the Trust.

Q1b. How many patients were initiated on Ruxolitinib (Jakavi) in the past 6 months for the following conditions? (Patients are classed as initiated if they have not received any of the below treatments in the previous 6 months)?

- **Polycythaemia Vera (ICD-10 code: D45)**

A1b. In the past 6 months there have been no patients initiated on Ruxolitinib (Jakavi) for Polycythaemia Vera in the Trust.

Q2a. How many patients were initiated on the following regimens for any condition in the past 6 months? (Patients are classed as initiated if they have not received any of the below treatments in the previous 6 months)?

- **Fedratinib**

A2a. In the past 6 months there have been no patients initiated on Fedratinib for any condition in the Trust.

Q2b. How many patients were initiated on the following regimens for any condition in the past 6 months? (Patients are classed as initiated if they have not received any of the below treatments in the previous 6 months)?

- **Momelotinib**

A2b. In the past 6 months there has been 2 patients initiated on Momelotinib for any condition in the Trust.

Q3a. How many patients were treated in the past 6 months for Polycythaemia Vera (ICD10 code D45) with?

- **Hydroxycarbamide**

A3a. The Trust is unable to provide the requested data for the number of patients that were treated in the past 6 months for Polycythaemia Vera with Hydroxycarbamide due to this being shared care with Primary Care. The prescribing will be within Primary Care.

Q3b. How many patients were treated in the past 6 months for Polycythaemia Vera (ICD10 code D45) with?

- **Interferon therapy**

A3b. In the past 6 months there has been 2 patients treated for Polycythaemia Vera with interferon therapy in the Trust.